Breaking news

Flo Health Secures $200M Investment From General Atlantic, Signaling A New Era In Femtech

In a landmark move for the femtech industry, Flo Health has secured a $200 million investment from General Atlantic, a leading global growth equity firm. This significant capital infusion marks a pivotal moment for the company, underscoring the growing recognition and potential of technology dedicated to women’s health.

Founded in 2015, Flo Health has swiftly risen to prominence with its innovative mobile application designed to track menstrual cycles, ovulation, and overall reproductive health. The app has garnered over 230 million downloads globally, making it a crucial tool for millions of women seeking to manage their health more effectively. This investment from General Atlantic is poised to propel Flo Health into its next phase of growth, enabling it to expand its product offerings and enhance its technological capabilities.

General Atlantic’s decision to invest such a substantial sum is indicative of the broader trends within the femtech sector. The femtech market, which includes a range of products and services aimed at improving women’s health, is projected to grow exponentially over the next decade. The increasing awareness of women’s health issues, coupled with advancements in technology, has created a fertile ground for innovation and investment. By backing Flo Health, General Atlantic is not only supporting a single company but also signalling confidence in the sector’s future.

Yaroslava Goncharova, CEO of Flo Health, expressed enthusiasm about the partnership with General Atlantic, stating, “This investment will allow us to accelerate our mission of improving the health and wellbeing of women globally. We are excited to leverage General Atlantic’s expertise and resources to further enhance our product and reach more women around the world.”

Flo Health’s success is rooted in its user-centric approach, leveraging data science and artificial intelligence to provide personalised health insights. The app’s features include symptom tracking, health predictions, and educational content, all designed to empower women with knowledge about their bodies. With the new funding, Flo Health plans to deepen its AI capabilities, enhance its user experience, and expand its educational content, ensuring it remains at the forefront of the femtech industry.

General Atlantic, known for its strategic investments in technology and healthcare, sees Flo Health as a strategic addition to its portfolio. Sandeep Naik, Managing Director and Head of India & Southeast Asia at General Atlantic, highlighted the potential for growth in the femtech space. “Flo Health is at the intersection of healthcare and technology, addressing a significant market need with its innovative solutions. We believe in the company’s vision and are committed to supporting its growth trajectory.”

The $200 million investment also reflects a broader shift in the investment landscape, where gender-specific health solutions are gaining traction among investors. The femtech sector, which has historically been underfunded, is now witnessing increased interest and funding, signalling a positive change in how women’s health is valued and supported.

Flo Health’s journey from a startup to a leading player in femtech exemplifies the transformative potential of technology in healthcare. With General Atlantic’s backing, the company is well-positioned to continue its upward trajectory, driving innovation and improving health outcomes for women worldwide. As Flo Health embarks on this new chapter, the femtech industry will undoubtedly be watching closely, anticipating the strides the company will make in advancing women’s health.

LVMH Revenue Rises, But China Weakness Continues To Weigh On Luxury Giant

A Softer Quarter Exposes The Limits Of Luxury’s Recovery

LVMH, the world’s largest luxury group and parent of Louis Vuitton, Dior, Celine and Hennessy, reported revenue of €18.5 billion in the three months to the end of September, underscoring both the scale of its business and the pressure building across parts of the luxury market.

The company’s revenue rose 1.2% year on year in the third quarter, following a 0.1% increase in the second quarter and a 5.9% decline in the first. The trajectory points to stabilization, but not yet to a convincing rebound.

Organic Growth Misses Expectations

Organic sales growth, which strips out currency effects and portfolio changes, slowed to 1% in the third quarter from 3% in the previous quarter. That result fell short of market expectations and reinforced concerns that the luxury cycle remains uneven.

For the first nine months of the year, LVMH generated sales of €57.1 billion, with organic growth of 2%.

In its statement, the company highlighted the breadth of its portfolio, saying that diversification continues to provide resilience in an uncertain geopolitical and economic environment. That remains one of LVMH’s defining strengths: when one category weakens, another can help offset the downturn.

China Remains The Key Pressure Point

LVMH said sales performed well in the United States, Europe and Japan, but conditions in China remained less favorable. That matters because the country has long been one of the most important growth engines for global luxury brands.

The fashion and leather goods division, LVMH’s most closely watched unit, saw organic sales fall 5% as weaker demand in China weighed on performance. Deutsche Bank said the decline was steeper than the roughly 2% drop expected by analysts.

The segment had delivered its first organic sales gain in two years in the previous quarter, making the latest retreat a notable setback.

Brand Equity Faces A Test In China

The quarter also highlighted the reputational risks facing global brands in China. Louis Vuitton drew criticism after suing local tea company Molly Tea over logo copying. Although the company won the case, the dispute sparked social media backlash and boycott calls, adding another layer of pressure to an already fragile environment.

For a company built on scarcity, aspiration and brand discipline, perception is an asset as valuable as inventory. In a market as digitally connected as China, that asset can shift quickly.

Mixed Performance Across The Portfolio

Not every division weakened. LVMH’s selective retailing business, which includes Sephora, posted an 8% organic sales increase. Watches and jewellery, along with wines and spirits, both recorded 6% organic gains.

That broad mix is precisely what has historically given LVMH an advantage over rivals: it can absorb softness in one category without relying on a single growth driver.

Analysts See A Longer Recovery Ahead

Deutsche Bank analysts said the results could lead to further cuts in earnings forecasts for the second half of 2026 and 2027. They added that it is difficult to see what could improve investor sentiment in the near term.

Still, the bank framed the weakness as cyclical rather than structural. In its view, recovery is taking longer because Chinese demand remains subdued, but the problem does not appear to reflect a permanent deterioration in the brand franchise. Analysts said ongoing brand initiatives are beginning to show results, though improvements are likely to remain gradual.

Investor Pressure Continues To Mount

LVMH’s share price has fallen nearly 40% since the start of the year. In September, L’Oréal overtook the group as France’s most valuable listed company, a symbolic shift that captures how sharply sentiment has changed.

Shares in LVMH were down more than 1.6% in Paris around 10 a.m. CEST following the release.

eCredo
Uol
Aretilaw firm
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter